{"description":"2000\u5e74\u4ee5\u6765230\u4e07\u4ef6\u306e\u85ac\u306b\u3088\u308b\u4e2d\u7d76\u304c\u884c\u308f\u308c\u3046\u306124\u4eba\u304c\u6b7b\u4ea1 \u4ee5\u4e0b\u304b\u3089\u53d6\u3063\u305f\u6570\u5024\u306e\u3088\u3046\u3067\u3059\u3002Analysis of Medication Abortion Risk and the FDA report \u201cMifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018\u201d","provider_name":"Hatena Blog","title":"Analysis of Medication Abortion Risk and the FDA report","published":"2022-02-03 17:08:54","version":"1.0","categories":[],"blog_title":"\u30ea\u30d7\u30ed\u306a\u65e5\u8a18","url":"https://okumi.hatenablog.com/entry/2022/02/03/170854","author_name":"okumi","author_url":"https://blog.hatena.ne.jp/okumi/","provider_url":"https://hatena.blog","image_url":null,"width":"100%","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fokumi.hatenablog.com%2Fentry%2F2022%2F02%2F03%2F170854\" title=\"Analysis of Medication Abortion Risk and the FDA report - \u30ea\u30d7\u30ed\u306a\u65e5\u8a18\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","type":"rich","height":"190","blog_url":"https://okumi.hatenablog.com/"}